+ Follow NOVARTIS ONCOLOGY Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 779855
[Title] => Novartis, NKTI tie up to help GEP NET patients
[Summary] => Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 464588
[Title] => Reducing risk of cancer returning in patients
[Summary] => MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
NOVARTIS ONCOLOGY
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 779855
[Title] => Novartis, NKTI tie up to help GEP NET patients
[Summary] => Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 464588
[Title] => Reducing risk of cancer returning in patients
[Summary] => MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
February 23, 2012 - 12:00am